Extrovis AG and Dr. Reddy's Laboratories have announced the launch of Fluorouracil Cream, 0.5 percent, an authorised generic and therapeutic equivalent of Carac (fluorouracil cream) 0.5 percent, in the US market.

Manufactured in Texas at one of Extrovis’ facilities and approved by the US Food and Drug Administration (USFDA), Dr. Reddy’s Fluorouracil Cream, 0.5 percent, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

“This product generic launch marks a key milestone in our commitment to increasing patient access and long-term value creation for the US healthcare system. Our partnership with Dr. Reddy’s helps ensure that patients and healthcare providers in the United States have continued access to a high-quality and cost-effective product,” said Hans R. Kamma Co-CEO and Chief Strategy Officer of Extrovis AG.  

Raghavendra Rao PV, Chief Financial Officer of Extrovis AG, acknowledged Dr. Reddy’s deep expertise in commercialisation and distribution within the US market.  

“This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly,” he said.